Pharmaceuticals
News Category
VERAXA Biotech Receives Positive Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
VERAXA Biotech announced Scientific Advice from Germany's Paul-Ehrlich-Institute, validating its dual-targeting BiTAC-TCE platform and supporting its ...
Siegfried Appoints Eduardo Montanha as COO to Drive Integrated Operations Strategy
Siegfried appoints Eduardo Montanha as Chief Operating Officer to lead its global manufacturing network, supporting the company's strategy to offer in...
NextPlat Corp Expands PharmcoRx With Planned Florida Pharmacy Acquisition, Targeting Underserved Rural Market
NextPlat Corp acquires a rural Florida pharmacy for $1.5 million to expand PharmcoRx into an underserved market, leveraging same-day delivery and 340B...
Onco-Innovations Completes Reference Standard Program for ONC010, Bolstering CMC Framework
Onco-Innovations Limited announced the successful completion of an analytical reference standard program for its lead oncology candidate ONC010, a key...
VERAXA Biotech Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership
VERAXA Biotech has initiated cell line development for its lead BiTAC(R) T-cell engager program by partnering with ATUM, marking a key step toward IND...
Sustained Release Polymers Market to Reach USD 7.8 Billion by 2036 as Drug Delivery Innovation Reshapes Pharmaceutical Strategies
The sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036 at a CAGR of 7.4%, driven by chroni...
VERAXA Biotech Details BiTAC Pipeline Progress and Partnering Strategy in First Half 2026 Update
VERAXA Biotech provided a corporate and pipeline update highlighting advancement of its proprietary BiTAC platform and growing interest from potential...
VERAXA Biotech Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
VERAXA Biotech announced the start of cell line development for its lead BiTAC T-cell engager program, aiming to reduce off-tumor toxicity in cancer t...
VERAXA Biotech's Antibody Platform Positions It for Strategic Partnerships Amid Strong Sector Deal Activity
The article highlights that VERAXA Biotech AG's technology platform in antibody-drug conjugates and T-cell engagers places it favorably for potential ...
Ace Therapeutics Launches Comprehensive Preclinical Pain Research Platform to Accelerate Analgesic Drug Development
Ace Therapeutics announces full-spectrum preclinical analgesic drug development services with validated in vivo pain models and integrated research ca...
Medios AG Closes Aschaffenburg Facility to Optimize Manufacturing Network Amid Margin Pressure
Medios AG is closing its Aschaffenburg facility and consolidating production to improve efficiency and profitability, affecting 32 employees.
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Trial for Major Depressive Disorder on Track
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trials for HLP003 in major depressive disorder, with topline data exp...
Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Contrast Drug Facility
Voyageur Pharmaceuticals has hired Fluor Corporation to conduct feasibility studies for an iodine extraction facility in Oklahoma and an integrated co...
Knight Therapeutics Repays $60 Million Credit Facility Used for Paladin Acquisition, Underscoring Strong Cash Flow
Knight Therapeutics (TSX: GUD) has fully repaid the $60 million drawn from its revolving credit facility in June 2025 to finance the acquisition of Pa...
Voyageur Pharmaceuticals Evaluates Three U.S. Sites for Integrated Iodine and Barium Contrast Media Manufacturing Facility
Voyageur Pharmaceuticals is evaluating sites in Oklahoma and Texas for a vertically integrated contrast media facility that could reduce costs and sec...
Earth Science Tech Inc. (ETST) Positions Itself at the Intersection of Telemedicine, Pharmacy, and Healthcare Services
Earth Science Tech Inc. (ETST) has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy ecosystem, emph...
Voyageur Pharmaceuticals Submits Multi-Year Exploration Permit for Frances Creek Barite Project, Advancing Toward Feasibility Study
Voyageur Pharmaceuticals has submitted a multi-year area-based exploration permit application for its Frances Creek barite project, including a 2,000-...
Voyageur Pharmaceuticals Closes $5 Million Private Placement for FDA Licensing and Project Development
Voyageur Pharmaceuticals has closed a non-brokered private placement raising $5,005,278.32 to fund FDA licensing for its barium contrast products, reg...
Kairos Pharma Expands Pipeline with CL-741 Acquisition and Details Clinical Progress in Mid-Year Update
Kairos Pharma announced plans to acquire worldwide rights to Phase 1-ready CL-741, an oral c-MET kinase inhibitor, and provided updates on its lead ca...
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Opportunities in BioMedWire Podcast
Quantum BioPharma's lead drug candidate Lucid-MS targets nerve damage in multiple sclerosis, with a Phase 2 trial upcoming, while its commercial produ...
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Multiple Sclerosis Program and Diversified Pipeline
Quantum BioPharma is progressing a clinical-stage multiple sclerosis program with a novel approach targeting demyelination, alongside a diversified po...
Redwood AI Gains DTC Eligibility and Engages IBN for Investor Awareness
Redwood AI Corp. announced DTC eligibility for its common shares to simplify U.S. trading and enhance liquidity, and engaged InvestorBrandNetwork for ...
Carmed Pharmaceuticals Gains CityBiz Feature as U.S. Expansion Accelerates
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol formulations, is expanding into the U.S. market, highlighted by ...
Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit to Accelerate AI-Powered Antibody Drug Discovery
Sino Biological's new XPressMAX™ kit enables ultra-fast, high-throughput protein synthesis in 3 hours, integrating with AI-driven screening to speed a...
NanoViricides Advances NV-387 Toward Phase II Trials for MPox and Other Viral Diseases
NanoViricides updates progress on broad-spectrum antiviral NV-387, with regulatory approval for Phase II MPox trial in DRC and FDA orphan drug designa...
NanoViricides Prices $2 Million Registered Direct Offering to Fund Clinical Development
NanoViricides has agreed to sell shares and warrants to an institutional investor for gross proceeds of $2 million, with funds likely supporting its l...
Lantern Pharma Raises $4.4 Million in Registered Direct Offering to Advance AI-Driven Precision Oncology
Lantern Pharma closed a $4.4 million registered direct offering, with potential for an additional $4.85 million from warrants, to fund its AI-powered ...
Tonix Pharmaceuticals to Present at Two Investor Conferences in May 2026
Tonix Pharmaceuticals announced its participation in two May investor conferences, highlighting its commercial-stage CNS and immunology pipeline, incl...
Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery
Lantern Pharma announced the expansion of its predictBBB platform into a Large Quantitative Model, providing a real-time molecular intelligence engine...
LIXTE Biotechnology Positions LB-100 as Novel Approach in Cancer Treatment Landscape
LIXTE Biotechnology Holdings is advancing LB-100, a first-in-class PP2A inhibitor, in multiple clinical trials for solid tumors with high unmet medica...
Soligenix Leverages Platform Technology to Streamline Drug Development for Multiple Indications
Soligenix Inc. uses its synthetic hypericin platform to target cutaneous T-cell lymphoma and psoriasis, demonstrating how platform-based drug developm...
PolyPeptide Shareholders Approve All Proposals at 2026 Annual General Meeting
PolyPeptide Group AG shareholders approved all board proposals, including re-election of directors and auditors, at the company's fifth annual general...
LIXTE Biotechnology Files 2025 Form 10-K, Highlights Transformational Year with Clinical Progress and Strategic Expansion
LIXTE Biotechnology Holdings (NASDAQ: LIXT) filed its 2025 Form 10-K, detailing a year of leadership changes, clinical advancement of its lead compoun...
LIXTE Biotechnology’s LB-100: The World’s Only Clinical-Stage PP2A Inhibitor Poised to Transform Cancer Treatment
LIXTE Biotechnology’s LB-100, the only clinical-stage PP2A inhibitor, shows promise in enhancing cancer therapy by sensitizing tumors to immunotherapy...
Lonza Nominates Stephen Fry as Independent Board Member
Lonza nominates Stephen Fry, former Eli Lilly executive, to its Board of Directors, bringing extensive pharmaceutical industry experience and expertis...
Voyageur Pharmaceuticals Advances Barium and Iodine Contrast Media Projects, Targeting 2027 U.S. Market Entry
Voyageur provides a corporate update on its vertically integrated barium and iodine contrast media projects, including progress on bankable feasibilit...
Soligenix Receives Positive EMA Opinion for Orphan Drug Designation of Dusquetide in Behçet's Disease
Soligenix announced that the European Medicines Agency's Committee for Orphan Medicinal Products issued a positive opinion for orphan drug designation...
NETHERTON NOW Campaign Surpasses 2 Million Views, Raising Global Awareness for Rare Disease Day
Quoin Pharmaceuticals' NETHERTON NOW awareness campaign has achieved 2 million video views and 24 million impressions, highlighting the urgent need fo...
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Oncotelic Therapeutics is highlighted in a BioMedWire editorial as its late-stage oncology and CNS programs align with the growing trend in biotech M&...
Helus Pharma Reports Positive Phase 2a SPL026 Data Published in Nature Medicine
Helus Pharma announced that Phase 2a trial results for SPL026, published in Nature Medicine, showed significant reduction in depressive symptoms in ma...
BioVaxys Reports Positive Phase 2 Data for Maveropepimut-S in Metastatic Bladder Cancer, Expanding Potential Beyond Ovarian Cancer
BioVaxys announced positive Phase 2 results for maveropepimut-S combined with pembrolizumab and low-dose cyclophosphamide in metastatic bladder cancer...
Quantumzyme Corp. Outlines 2025 Progress and 2026 Strategic Priorities, Including AI Focus and Name Change
Quantumzyme Corp. details its 2025 achievements in enzyme R&D and AI integration, and announces plans for a name change to Quantum Genesis AI Corp. as...
Creative Biolabs Upgrades Biosimilar Development and CDMO Platform for Enhanced Physicochemical and Biological Characterization
Creative Biolabs announces strategic upgrades to its biosimilar development and CDMO platform, offering comprehensive physicochemical and biological a...
Protheragen Expands Drug Analysis Services with Integrated Stability, Impurity, and Chemical-Physical Testing
Protheragen announces integrated drug analysis solutions combining stability studies, impurity testing, and chemical-physical tests to support pharmac...
Lixte Biotechnology to Present at DealFlow Discovery Conference, Highlighting Progress of Lead Cancer Drug LB-100
Lixte Biotechnology Holdings announced its participation in the DealFlow Discovery Conference, where CEO Geordan Pursglove will meet with investors as...
LIXTE Biotechnology Engages IBN to Enhance Corporate Communications
LIXTE Biotechnology Holdings (NASDAQ: LIXT) has hired IBN to expand its corporate communications reach, aiming to increase awareness of its lead cance...
Voyageur Pharmaceuticals Secures Exclusive Iodine Extraction Technology and Appoints Dr. Brian Mueller as Director of Chemistry
Voyageur Pharmaceuticals acquires exclusive rights to a proprietary iodine extraction technology and appoints its inventor, Dr. Brian Mueller, as Dire...
Tonix Pharmaceuticals Advances TNX-4800 Lyme Disease Prophylaxis Program Toward FDA Meeting
Tonix Pharmaceuticals provides an update on its TNX-4800 program for seasonal Lyme disease prophylaxis, planning an FDA meeting in 2026 and GMP manufa...